Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Expert Review of Vaccines is Scopus-indexed (Q1, CiteScore 9.9), WoS SCIE, DOAJ. Published by Taylor and Francis Ltd..
Checked against the index lists dated .
ISSN 1476-0584Verify ISSN ↗1744-8395Verify ISSN ↗
Publisher: Taylor and Francis Ltd.
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology | 39 / 328 | 88th | Q1 |
| Immunology | 42 / 243 | 82nd | Q1 |
| Drug Discovery | 28 / 161 | 82nd | Q1 |
| Molecular Medicine | 35 / 179 | 80th | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2002–present, best quartile Q1, CiteScore 9.9.
Expert Review of Vaccines is Q1 in Pharmacology (rank 39 of 328), Q1 in Immunology (rank 42 of 243) and Q1 in Drug Discovery (rank 28 of 161), by CiteScore 2025. It is ranked in 4 subject areas in all.
Expert Review of Vaccines is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 9.9, which places it in quartile Q1 at the 88th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.280, quartile Q1, with an H-index of 117.
Expert Review of Vaccines is published by Taylor and Francis Ltd. Its print ISSN is 1476-0584 and its online ISSN is 1744-8395.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Expert Review of Vaccines has an h-index of 131 and a 2-year mean of 5.23 citations per paper (OpenAlex). Its Scopus CiteScore is 9.9, quartile Q1. On 2-year citations it ranks #46 of 319 Scopus journals in Pharmacology.
Expert Review of Vaccines published 107 papers in 2025; its busiest recent year was 2021 with 190. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2025–2026), authors are most often from United States (23.2%), China (16.7%) and United Kingdom (11.9%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (0.6 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.